XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Total revenues, net $ 110,565,000 $ 2,168,000 $ 227,198,000 $ 213,288,000
Operating costs and expenses:        
Total cost of revenues 3,653,000 598,000 6,292,000 1,196,000
Research and development 111,231,000 114,695,000 222,662,000 255,667,000
Selling, general and administrative 129,154,000 59,523,000 235,519,000 125,330,000
Restructuring, impairment and related charges 805,000 2,891,000 1,375,000 6,291,000
Total operating costs and expenses 244,843,000 177,707,000 465,848,000 388,484,000
Loss from operations (134,278,000) (175,539,000) (238,650,000) (175,196,000)
Other income (expense), net:        
Interest income 3,898,000 5,195,000 9,283,000 9,270,000
Interest expense (37,637,000) (22,937,000) (79,778,000) (46,408,000)
Gain on deconsolidation of a subsidiary 0 126,294,000 0 126,294,000
Losses on extinguishments of debt 0 0 (21,155,000) (26,590,000)
Net loss from equity method investments (20,189,000) (7,925,000) (35,745,000) (7,925,000)
Other income (expense), net 6,548,000 (632,000) 14,779,000 8,851,000
Total other income (expense), net (47,380,000) 99,995,000 (112,616,000) 63,492,000
Loss before income taxes (181,658,000) (75,544,000) (351,266,000) (111,704,000)
Income tax expense 2,100,000 0 2,100,000 0
Net loss (183,758,000) (75,544,000) (353,366,000) (111,704,000)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests 1,855,000 2,088,000 4,041,000 3,032,000
Net loss attributable to common stockholders of BridgeBio $ (181,903,000) $ (73,456,000) $ (349,325,000) $ (108,672,000)
Net loss per share attributable to common stockholders of BridgeBio, basic $ (0.95) $ (0.39) $ (1.84) $ (0.59)
Net loss per share attributable to common stockholders of BridgeBio, diluted $ (0.95) $ (0.39) $ (1.84) $ (0.59)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic 190,517,215 187,586,680 190,332,261 183,145,995
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted 190,517,215 187,586,680 190,332,261 183,145,995
License and Services Revenue        
Total revenues, net $ 37,440,000 $ 2,168,000 $ 117,130,000 $ 213,288,000
Net Product Revenue        
Total revenues, net 71,501,000 0 108,240,000 0
Royalty Revenue        
Total revenues, net 1,624,000 0 1,828,000 0
Cost of License, Services and Royalty Revenue        
Operating costs and expenses:        
Total cost of revenues 805,000 598,000 1,410,000 1,196,000
Cost of Goods Sold        
Operating costs and expenses:        
Total cost of revenues $ 2,848,000 $ 0 $ 4,882,000 $ 0